Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 18, 2025

Recent advances in the treatment of non-alcoholic fatty liver disease with astragaloside IV.

View Full Paper
Ask AI
Bookmark
Share

Authors

HWHui WangYJYunqin JiangSWShiyun Wang

Discussion

Loading...

Member takes

Overview

This review highlights the potential of astragaloside IV in improving lipid metabolism and reducing inflammation in non-alcoholic fatty liver disease.

Key Points

  • Astragaloside IV shows promise in treating non-alcoholic fatty liver disease by improving insulin resistance.
  • The compound works through pathways like AMPK, significantly impacting lipid metabolism and inflammation.
  • Preclinical studies indicate AS-IV can mitigate liver steatosis and oxidative stress effectively.
  • Further clinical trials are necessary to establish AS-IV's efficacy and optimize its use with other treatments.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/689a02c9e6551bb0af8cce71https://doi.org/10.2478/acph-2025-0022
View Full Paper
Ask AI
Bookmark
Share